Highlights

  • CSL Limited (ASX:CSL) reported FY26 revenue of US$15.8 billion, down 1% at constant currency.
  • Underlying NPATA attributable to shareholders was US$3.1 billion, down 2% at constant currency.
  • The company reported a US$2.6 billion attributable statutory loss after restructuring and impairment charges.
  • FY27 guidance calls for revenue broadly in line with FY26 and approximately 5% underlying NPAT growth.

CSL Limited is a global biotechnology company operating plasma-derived therapies, influenza vaccines and treatments in iron deficiency and nephrology. The company's FY26 results and its October 2026 annual general meeting highlighted the effects of restructuring, asset impairments and differing performance across three businesses. During trading on 29 October 2026, CSL Limited (ASX:CSL) was quoted at approximately AUD 198.34, up 0.63% at 11:31 a.m. AEDT. Management's FY27 outlook places attention on immunoglobulin demand, manufacturing efficiency and competitive pressures facing its pharmaceutical portfolio.

Company Business

CSL Limited (ASX:CSL) reports through CSL Behring, CSL Seqirus and CSL Vifor. CSL Behring develops and distributes plasma-derived and recombinant therapies covering immunodeficiencies, bleeding disorders and other serious conditions. Plasma collection and fractionation capacity underpin this business, with operations spanning multiple countries.

CSL Seqirus manufactures and supplies influenza vaccines and related pandemic preparedness products, while CSL Vifor concentrates on iron therapies and nephrology treatments. The company also invests in research and development, manufacturing facilities and distribution networks. Demand, regulatory approval, reimbursement frameworks and production reliability affect results differently across the portfolio.

Recent Development

In August 2026, CSL Limited (ASX:CSL) reported a full-year statutory loss after recognising restructuring and impairment expenses. Its 27 October AGM presentation reiterated FY26 revenue of US$15.8 billion, underlying NPATA of about US$3.1 billion and cash flow from operations of US$3.5 billion. The presentation also described US$176 million of savings realised under the transformation program.

The company recorded US$799 million in one-off pre-tax restructuring costs and US$7.1 billion in pre-tax impairments during FY26. The charges reflected revised commercial assumptions, anticipated generic competition, regulatory developments and site-utilisation considerations. CSL also described the integration of Behring and Vifor commercial functions, alongside efforts to simplify operating infrastructure.

Other developments included a collaboration with Dutch biotechnology group VarmX and an intention to invest around US$1.5 billion in US plasma manufacturing, including the Horizon 2 yield initiative. CSL said additional clinical evidence would be sought to support regulatory approval for Horizon 2.

Financial Performance and Sector Context

For the year ended 30 June 2026, CSL Limited (ASX:CSL) generated US$15.797 billion of total operating revenue, compared with US$15.558 billion in FY25 on a reported-currency basis. On CSL's constant-currency comparison, revenue declined 1%. Underlying NPATA attributable to shareholders was US$3.098 billion, down 2% at constant currency. Reported net loss attributable to shareholders was US$2.579 billion, versus a US$3.002 billion profit in FY25.

CSL Behring revenue totalled US$11.387 billion, down 1% at constant currency. Immunoglobulin sales were US$6.2 billion and broadly flat, while albumin sales fell 17% amid Chinese government cost-containment measures. The company's hereditary angioedema treatment ANDEMBRY generated US$240 million in its first full year in market.

CSL Vifor revenue reached US$2.379 billion, up 3% at constant currency, with nephrology growth partly offset by generic pressure in iron products. CSL Seqirus revenue was US$2.031 billion, down 8%, reflecting the absence of earlier avian-influenza-related revenue. Seasonal influenza vaccine sales nevertheless rose 4% at constant currency.

Operating cash flow was US$3.512 billion, while the company reported net assets of US$16.3 billion and a net-debt-to-EBITDA leverage ratio of 1.8 times. CSL maintained its FY26 total dividend at US$2.92 per share and completed an A$1 billion buyback.

Risks to Consider

CSL Limited (ASX:CSL) remains exposed to plasma collection costs, manufacturing efficiency, product safety and regulatory decisions. Generic competition and reimbursement changes can affect pricing and sales, particularly at CSL Vifor. Lower vaccination rates or changing government procurement may influence Seqirus revenue. Execution risks also arise from restructuring, new facilities, product development and the evidence required for regulatory submissions. Foreign exchange changes affect reported financial comparisons.

What to Watch Next

For FY27, CSL expects group revenue broadly in line with FY26 and approximately 5% underlying NPAT growth at constant currency. Behring is expected to deliver mid-single-digit revenue growth, with immunoglobulin growth at mid-to-high single digits. Seqirus anticipates low-single-digit growth, while Vifor expects an approximately 25% decline as generic competition, reimbursement changes and the loss of TAVNEOS marketing authorisation affect the business.

Subsequent CSL Limited (ASX:CSL) disclosures will indicate whether plasma productivity initiatives, transformation savings and new-therapy uptake are progressing as planned. The timing of regulatory and manufacturing milestones will also be material to operational reporting.

Key Insights

CSL's FY26 performance combined largely unchanged overall revenue at constant currency with substantial impairment charges and a statutory loss. Cash generation remained positive, while segment trends diverged between Behring, Vifor and Seqirus. For CSL Limited (ASX:CSL), the principal measurable indicators are immunoglobulin volumes, cost-savings delivery, Vifor's response to competition and progress towards FY27 guidance.